Explore the latest research on the combination of ropeginterferon alfa-2b with anti-PD1 blockade as adjuvant therapy in HBV-related hepatocellular carcinoma (HCC). This study provides important insights into the potential synergistic effects of immunomodulation and checkpoint inhibition in improving post-operative outcomes.
🔗 Read the full article: https://link.springer.com/article/10.1007/s12072-025-10954-9